Background: The microenvironmental biomarkers of different subtypes of ovarian cancers arising from endometriosis have not been studied in Taiwan. Their expression can help in understanding the carcinogenic mechanism. Methods: Our study used immunohistochemistry to compare the expression of estrogen receptor (ER), hepatocyte nuclear factor-1 beta (HNF1ß), p53, phosphatase and tensin homolog (PTEN), BAF250a, and cyclooxygenase-2 (COX-2) among 79 cases of endometriosis-associated ovarian cancers, including 40 (50%) clear cell carcinomas (CCCs), 33 (41%) endometrioid (EM) adenocarcinomas, four (5%) serous carcinomas, one adenosquamous carcinoma, and one adenosarcoma. Results: Positive stainings for ER, HNF1ß, p53, and COX-2 were identified in 34 (43%), 30 (38%), 10 (13%), and 44 (56%) cases. Loss of PTEN and BAF250a were noted in 29 (37%) and 37 (47%) cases. The expression of ER was reversely correlated with that of HNF1ß (rho ¼ À0.417, p < 0.001) and correlated with p53 (rho ¼ 0.284, p ¼ 0.011). ER positivity was commonly identified in EM adenocarcinomas (91%), and rarely in CCCs (8%) and serous carcinoma (0%; p < 0.001). By contrast, HNF1ß expression was frequently noted in CCCs (65%) and serous carcinomas (50%), but less in EM adenocarcinoma (6%; p < 0.001). All staining results were similar between atypical endometriosis glandular epithelium and contiguous malignant parts. Only nine cases showed 10 minor differences (10/474, 2%) in ER, HNF1ß, and BAF250a. For the staining patterns of p53, COX-2, and PTEN, there was no difference between the invasive and precursor parts. Conclusion: Our results supported the suggestion that estrogen-dependent ovarian cancer arising from endometriosis is substantially more associated with EM adenocarcinoma than CCCs. The positive HNF1ß staining was a frequent finding in CCCs, but not in EM adenocarcinoma. The similar staining patterns of atypical endometriosis glandular cells with the invasive parts confirmed their precursor status.
Introduction
Endometriosis is a common gynecologic disease, affecting approximately 10e15% of women in reproductive years. 1 Although endometriosis generally follows a benign course, its malignant potential and specific association with ovarian cancer has been documented in prior studies.
2e5 These endometriosis-associated ovarian cancers are predominantly clear cell and endometrioid (EM) histologic subtypes. Van Gorp et al 6 classified ovarian cancer associated with endometriosis into three categories: (1) ovarian cancers with histologic proof of transition from endometriosis to ovarian cancer, based on the definition of Sampson 7 and Scott 8 ; (2) ovarian cancer with endometriosis in the same ovary, but without histologic proof of transition; and (3) ovarian cancers with concomitant endometriosis at any location in the pelvis. Ovarian cancers arising from endometriosis were only confirmed if they fulfilled the above criteria for category (1) of endometriosis-associated ovarian cancers. The frequency of malignant transformation of endometriosis has been estimated as 0.7e1.6%, 4, 9 suggesting that only a small proportion of endometriosis has the potential to progress into carcinoma.
Recent molecular and pathological evidence suggested that endometriosis serves as a precursor, and some molecular events and microenvironmental factors were reported, including the estrogen effect, hepatocyte nuclear factor-1 beta (HNF1ß) activation, p53 alteration, phosphatase and tensin homolog (PTEN) silencing, AT-rich interactive domain 1A (ARID1A) mutation, and cyclooxygenase-2 (COX-2) overexpression. 10e16 The roles of the above molecular events and microenvironmental factors in the carcinogenesis of malignant transformation have never been studied in Taiwan. In the current study, by using immunohistochemical stains for estrogen receptor (ER), HNF1ß, p53, PTEN, BAF250a, and COX-2, we tried to investigate the relationship of these molecular alterations and microenvironmental factors among: (1) the different subtypes of ovarian cancers arising from endometriosis; and (2) the atypical endometriosis glands and the contiguous invasive areas. The results can provide helpful information for a better understanding of the carcinogenic mechanism of these ovarian cancers arising from endometriosis in Taiwan.
Methods
This is a retrospective study of information obtained from the archives of the Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, from January 2001 to December 2011. The study was approved by the hospital administration. After an independent pathological review by three well-qualified pathologists, a total of 79 consented cases of ovarian cancers arising from endometriosis, which fulfilled the definition described by Van Gorp et al, 6 were included. Of the 79 cases, there were 33 (41%) EM adenocarcinomas, 40 (50%) clear cell carcinomas (CCC), four (5%) serous carcinomas, one adenosquamous carcinoma, and one adenosarcoma. After the histopathological examination, the paraffin blocks which revealed the continuity of malignant transformation from endometriosis to cancer, were retrieved. The immunohistochemical stains for ER, HNF1ß, p53, PTEN, BAF250a, and COX-2 were performed.
Sections 4 mm thick, from selected formalin-fixed paraffinembedded blocks, were assessed by immunohistochemistry. The antibodies and each dilution used in this study are listed in Table 1 . The sections were stained on an automated system (BOND-MAX system, Leica, Newcastle, UK) as per the manufacturer's protocol, with test and validation sets stained at different times and the detection kit was Bond (Leica) Polymer Refine Detection.
The results of the immunohistochemistry were documented by the percentage of positive cancer cells along with the staining intensity as: negative; 1þ (focal weakly positive); 3þ (diffuse strongly positive), and 2þ (in-between). Loss of PTEN and BAF250a expression was defined as totally negative staining of the abnormal epithelial cells. The stainings of ER, HNF1ß, and COX-2 were classified as positive when a staining result over 1þ was found. 17, 18 For p53, the presence of diffuse strong nuclear staining has been reported more specifically to correlate with the presence of Tp53 mutations, so we set 3þ as the relevant cut-off level for p53 staining, similar to the cut-off used in Alkushi et al. 19 The Fisher's exact test was used for comparisons of categorical data and the correlation between the expression of these markers was calculated by Spearman's rank correlation coefficient.
Results
The immunohistochemical profiling for these 79 cases is summarized in Table 2 . ER positive results were more often identified in EM adenocarcinomas (30/33, 91%) than in CCCs (3/40, 8%) and serous carcinomas (0/4, 0%). By contrast, the HNF1ß expression was more often noted in CCCs (26/40, 65%) and serous carcinomas (2/4, 50%) than in EM adenocarcinomas (2/33, 6%; Fig. 1 ). Positive staining for p53 was more frequently found in serous carcinomas (1/4, 25%) and EM adenocarcinomas (8/33, 24%) than in CCCs (1/40, 3%). A loss of PTEN was more often noted in serous carcinomas (4/4, 100%) and EM adenocarcinomas (15/33, 46%) than in CCCs (9/40, 23%). Positive staining for COX-2 and loss of BAF250a expression revealed no statistical significance among different subtypes (Fig. 2) . The expression of ER was reversely correlated with that of HNF1ß (Spearman's rank correlation coefficient rho ¼ À0.417, p < 0.001) and correlated with p53 (rho ¼ 0.284, p ¼ 0.011). The expressions between other makers had no significant correlation.
The staining results were similar between atypical endometriosis glandular epithelium and contiguous malignant parts (Fig. 3) . Only nine cases showed 10 minor differences in total 474 stains (2%), including ER, HNF1ß, and BAF250a. For the staining patterns of p53, PTEN, and COX-2, there was no difference between the invasive and precursor parts (Table 3 ).
Discussion
In the current study, we chose ovarian cancers arising from endometriosis which showed transformation zones from the atypical endometriosis glands to their contiguous malignant areas, for evaluating the expression of ER, HNF1ß, p53, PTEN, BAF250a, and COX-2 in both areas of precursors and invasive parts. ER positivity was often identified in EM adenocarcinomas (91%), whereas HNF1ß expression was frequently noted in CCCs (65%) and serous carcinomas (50%). All of the staining results were similar between atypical endometriosis glandular epithelium and contiguous malignant parts.
The frequency of the histological types in the current report is similar to that which has been previously reported.
8 CCC (50%) and EM adenocarcinoma (41%) were common, whereas other types of ovarian cancers are rarely seen in endometriosis-associated ovarian cancers. Interestingly, there was a case of adenosarcoma in our series, but this type of cancer was not observed in the previous reports. Almost all the endometriosis associated ovarian cancers were of epithelial origin and supposed to come from the precursors of atypical endometriosis. The pathogenesis and the origin of the malignant part of adenosarcoma and sarcoma, rather than carcinoma, need further study.
Although both EM and CCC were commonly seen in the ovarian cancers arising from endometriosis, their molecular events are not the same. Unopposed estrogen is associated with an increased risk of endometrial cancer, and several studies have suggested that it is also associated with the malignant transformation of endometriotic cysts. 20 Our results showed ER positivity in 91% of EM adenocarcinomas, but only in 8% of CCCs and 0% of serous carcinomas. This revealed that the estrogen effect has a much stronger relationship to the EM adenocarcinomas, and it played little role in the carcinogenesis of CCC and serous carcinoma. On the contrary, HNF1ß was positive in 65% of CCCs but only in 6% of EM adenocarcinomas. This finding supports the fact that HNF1ß can be a potential marker for ovarian CCCs. 17, 21, 22 Besides, HNF1ß is also expressed in the precursors, such as borderline as well as atypical endometriosis, suggesting that the expression is specifically related to the clear cell lineage, and is demonstrable at the very early phases of its oncogenesis. 23 Our results showed no significant difference of the HNF1ß expression between the atypical endometriosis and contiguous malignant parts concurred with their studies. 23 Mandai et al 11 speculated that persistent exposure to oxidative stress and inflammation results in a stress-resistant and slow-growing phenotype of malignancy, i.e., CCC. To date, patients with CCC have a significantly worse prognosis than patients with non-CCC, because of their low response to standard platinum-based chemotherapy. 22, 24 HNF1ß might be a specific molecular target for the therapy of ovarian CCC in Fig. 2 . Examples of immunohistochemical stainings of p53, phosphatase, and tensin homolog (PTEN), BAF250a, and cyclooxygenase-2 (COX-2) in clear cell carcinomas (CCC) and endometrioid (EM) adenocarcinomas. In CCC, p53 is usually negative but sometimes moderately positive (A); in EM adenocarcinomas, p53 is often positive (E). Loss of PTEN is a more common finding in EM adenocarcinomas than in CCC (F and B). Complete loss of BAF250a is frequently noted both in CCC and EM adenocarcinomas (C and G). COX-2 is usually positive both in CCC and EM adenocarcinomas (D and H). the future, especially in those cancers arising from endometriosis. Although, 50% (2/4) serous carcinoma cases also revealed positive HNF1ß staining, the extent of such cells was no more than 10% of the total cancer cells. In addition, the case number was too limited to make a conclusion about the presentation of serous carcinoma. More cases are needed in future studies.
The tumor suppressor gene p53 was expressed in 13% of the study cases, a figure less than those in previous reports (around 40e50%), 11 which may be due to different study cases and criteria to define p53 positivity. Its expression was more common in EM and serous types of carcinoma than CCC (24e25% vs. 3%). Our data further concurred with the existing proposition that alteration in p53 expression may play a role in malignant transformation of endometriosis, especially in EM and serous types of carcinoma.
COX-2 is implicated in early events of neoplastic transformation; it is rarely found in normal ovarian surface epithelia, but is present in endometriosis and in ovarian inclusion cysts considered to be premalignant. 25 Our previous report also revealed similar results. 26 In the current study, we further confirmed that COX-2 expression was noted in 56% of the ovarian carcinomas arising from endometriosis, consistent with previous studies (42e83% of ovarian cancers). Its expression had no significance among different subtypes and no correlations with other markers.
There were PTEN mutations in 20.6% of ovarian endometriotic cysts and 20% of ovarian EM adenocarcinomas reported by Sato et al. 27 Our study revealed that considerably more cases showing PTEN loss were commonly seen in EM and serous types, than in CCCs (46e100% vs. 23%). Different study populations and methodologies may explain this discrepancy, such as the brands of antibodies and the interpretation criteria. More cases are needed for further evaluation of this phenomenon. ARID1A mutation, expressed by the loss of the corresponding protein BAF250a, is a newly identified tumor suppressor gene in ovarian clear cell and EM carcinomas. Jones et al 28 found ARID1A mutations in 57% (24/42) of ovarian CCCs. In Wiegand et al's report, 29 they conducted an ARID1A mutation analysis in large numbers of ovarian carcinomas and the mutations were seen in 46% (55/119) of CCC, in 30% (10/ 33) of EM adenocarcinomas, and in none of the 76 high-grade serous carcinomas. However, in another recent study, 30 using tissue microarrays, the loss of BAF250a was also noted in uterine Grade 3 EM (39%), clear cell (26%), and serous carcinomas (18%). In the current study, loss of BAF250a was noted in 47% of cases; its expression had no significance among different subtypes and no correlations with other markers.
It is increasingly evident that chronic inflammation, coupled with genetic alteration, promotes the progression of a malignant endometriosis-associated carcinoma phenotype. Until now, our study was the first series which conducted this molecular marker analysis on all cases, with histologic proof of the transition from endometriosis to ovarian cancer, not just associated lesions. The staining results were similar between atypical endometriosis glandular epithelium and contiguous malignant parts. Only nine cases (9/79, 11%) showed 10 stains (10/474, 2%), with minor differences in ER, HNF1ß, and BAF250a. For the staining patterns of p53, PTEN, and COX-2, they were totally identical for the invasive and precursor parts. The above findings further confirmed the concept that these cancers are derived from endometriosis and share common molecular and genetic features between precursors and invasive lesions.
In conclusion, the current Taiwan series study revealed a similar incidence of the subtypes of ovarian cancers arising from endometriosis with other previous reports. Many questions still need to be answered as to the exact pathogenesis of how endometriotic cysts develop into endometriosisassociated ovarian carcinomas. However, the possible mechanisms and attributing factors, including longstanding unopposed estrogen stimulation, repeated incessant menstruation leading to epithelial damage and repair in an inflammatory oxidative stress microenvironment, and some early molecular events, were demonstrated. Whether we can use these biomarkers as risk factors to help identify high risk endometriosis or provide information to improve the therapeutic effect, will be the primary challenges in future studies. Table 3 The staining difference between atypical endometriosis glandular epithelium (precursor) and contiguous malignant parts. 
